Cellectis Stock

Cellectis FCF Margin

The Free Cash Flow Margin of Cellectis (ALCLS.PA) as of Sep 4, 2026 is 38.90 %. In the previous year, Free Cash Flow Margin was -280.85 % — a change of -113.85% (higher).

FCF Margin

38.90 %

YoY

-113.85%

Last updated:

Free Cash Flow Margin of Cellectis is 2026 38.90 % . Free Cash Flow Margin of Cellectis was 2025 -280.85 % . It decreases by -113.85% higher compared to the previous year.

The Cellectis FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2017
-170.79 USD
Jan 1, 2018
-340.72 USD
Jan 1, 2019
-442.77 USD
Jan 1, 2020
-223.67 USD
Jan 1, 2021
-322.06 USD
Jan 1, 2022
-349.41 USD
Jan 1, 2023
-280.85 USD
Jan 1, 2024
38.90 USD
The Cellectis FCF Margin history
YEARFCF MarginYoY
38.90 %-113.85%
-280.85 %-19.62%
-349.41 %+8.49%
-322.06 %+43.99%
-223.67 %-49.48%
-442.77 %+29.95%
-340.72 %+99.50%
-170.79 %+12.03%
-152.44 %+11,502.93%
-1.31 %-100.70%
187.88 %
Access this data via the Eulerpool API

Cellectis Stock analysis

What does Cellectis do? Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellectis stock

Free Cash Flow Margin of Cellectis is 38.90 % in 2026.

Free Cash Flow Margin of Cellectis changed from -280.85 % to 38.90 %, representing a -113.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Cellectis since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Cellectis with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Cellectis

All Key Metrics — Cellectis